Stock Events

Atyr Pharma 

€1.72
0
-€0.09-4.97% Thursday 07:11

Statistics

Day High
1.72
Day Low
1.72
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
100.72M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.47
-0.38
-0.29
-0.2
Expected EPS
-0.24
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 471A.F. It's not an investment recommendation.

About

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Employees
65
Country
US
ISIN
US0021202025
WKN
000A2PM86

Listings